top of page
gradientForSurfBreak.png

Item List

EIN News
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007

xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). Oblato is currently developing OKN-007 as a treatment for glioblastoma multiforme (GBM).

Recent Posts

Portfolio Company

Carlsmed.png

xCures showcases the Power of its Real-time Clinical data platform at ASCO Annua ...

Newswire EIN

Portfolio Company

Carlsmed.png

Tracy MacNeal Of Materna Medical On Five Things We Must Do to Improve the US Hea ...

Medium

Portfolio Company

Carlsmed.png

UptimeHealth teams up with Dental Health Products, supporting access to vital su ...

Newswire EIN

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page